Island Pharmaceuticals is pursuing FDA approval for Galidesivir, an experimental broad-spectrum antiviral being developed to treat Marburg virus disease through the FDA’s Animal Rule pathway, which allows certain drugs to be evaluated using animal efficacy data when human trials are not feasible or ethical. If approved, Galidesivir could qualify for a priority review voucher and potentially lead to U.S. government procurement contracts for emergency preparedness and stockpiling. The company is preparing studies at the U.S. Army Medical Research Institute of Infectious Diseases and Texas Biomedical Research Institute, while also exploring emergency-use access for patients affected by a Bundibugyo Ebola outbreak in Uganda.
